J. C. Jaime

发表

Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double‐Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation‐Positive Metastatic Non–Small‐Cell Lung Cancer

L. Paz-Ares, M. Reck, K. Nakagawa, 2017, Clinical lung cancer.

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

K. Nackaerts, Siân Jones, A. Chiang, 2020 .

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for Small-Cell Lung Cancer: Primary and Correlative Biomarker Analyses.

K. Nackaerts, Siân Jones, A. Chiang, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.

Keunchil Park, N. Rizvi, J. Mazières, 2020, Lung cancer.

Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.

Ying Cheng, T. Mok, R. Rosell, 2018 .

Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

J. Machiels, L. Dirix, L. Paz-Ares, 2014 .

First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer

M. Socinski, D. Carbone, S. Peters, 2017, The New England journal of medicine.

Prospective study of oncogenic mutations in circulating cell-free DNA (cfDNA) using a multiplex sequencing platform for patient (pt) allocation to phase I clinical trials.

J. Bono, U. Banerji, S. Kaye, 2012 .

Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.

K. Kiura, L. Paz-Ares, M. Reck, 2017, Clinical lung cancer.

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer

L. Paz-Ares, C. Visseren-Grul, J. C. Jaime, 2010, BMC Cancer.

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

D. Bermejo-Peláez, M. Ledesma-Carbayo, A. Muñoz-Barrutia, 2023, Journal of Translational Medicine.

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

Ying Cheng, T. Mok, Yi-long Wu, 2017 .

Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

J. Machiels, L. Dirix, L. Paz-Ares, 2014 .

Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging (NCT009794131).

K. Harrington, N. Tunariu, T. Yap, 2012 .

Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.

T. Zander, J. Machiels, J. Schellens, 2016 .

L. Paz-Ares, C. Visseren-Grul, J. C. Jaime, 2010, BMC Cancer.